Corporate / CVC · 2 deals
Melbourne, VIC
Every published round CSL took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies CSL has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| ENA Respiratory | Antiviral nasal spray to prevent severe respiratory viral infections | 27 Sep 2020, Series A | 1 | 0 |
| Denteric | 26 Sep 2019, Series A | 1 | 0 |
Fund closes reported for CSL, as distinct from the investments it has made.
Companies CSL has backed that another company then bought. An exit for the holding, not a deal CSL did.
| Name | Role | Sources |
|---|---|---|
| Dr Andrew Nash | Chief Scientific Officer and Global Head of Research (former) | Brandon BioCatalyst, @AuManufacturing, Brandon BioCatalyst portfolio, Brandon Capital portfolio, Startup Daily |
| Justin Cahill | Divisional Chief Financial Officer (former) | @AuManufacturing |
Stories naming CSL. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech Paradigm Biopharmaceuticals appoints rheumatology specialist Daniel Furtner as chief medical officer; predecessor Donna Skerrett stays as senior scientific advisor, and the firm's late-stage osteoarthritis trial has finished enrolling 538 participants.
Acrux has hired Dr Jolanta Airey as chief medical officer, adding clinical leadership as the company prepares late-stage trials in the United States for its women's testosterone therapy.
Avecho Biotechnology brings in a former CSL dealmaking executive as a consultant to help license its Phase 3 CBD insomnia capsule internationally.
An AFR managed-funds topic page: a star small-caps deputy goes solo with a new Sydney firm, Gigacomm buys rival DGtek, Google plans a multibillion-dollar domestic bond, plus fund manager and market stories.
Brandon Capital's blog interviews Denteric's operating chief about its gingipain-targeting therapy for periodontitis, trial progress, and its origins in University of Melbourne oral health research.
An analysis of what Australian long-horizon research commercialisation requires, citing Gilmour Space, Cochlear and BluGlass as illustrations of patient capital and ecosystem support needs.
Novartis is acquiring London biotech Myricx Bio for US$1.1 billion upfront plus milestone payments, handing Melbourne venture firm Brandon Capital a record return on the startup it seeded in 2019.
Also Forbes Australia
Breakthrough Victoria's chief executive marks his first year, tallying 70 investments, university and fellowship programs, a Jumar Bioincubator grant with partners, and looks ahead to a consolidated Victorian innovation entity.
Profile of Percheron Therapeutics, an ASX-listed biotech led by Dr James Garner, developing HMBD-002 against the VISTA protein to treat cancers that resist PD-1 immunotherapy, with Phase 2 trials planned for 2026.
Brandon BioCatalyst has named Peter Beattie its chair as Bill Ferris retires, with Andrew Nash joining the board and Ross King becoming deputy; manager Brandon Capital's newly raised $439 million fund was noted.
Australia's NRFC has injected $150m into Brandon Capital's sixth life-science vehicle, lifting it to a $439m close; past NRFC cheques to local deep-tech firms are also recapped.
Brandon Capital has completed a A$439 million final close for its sixth life sciences fund, bringing the National Reconstruction Fund Corporation and WA Government in alongside backers such as HESTA, Hostplus, CSL and QIC.
MTPConnect's government-backed accelerator program has awarded $12.07 million in non-dilutive grants to 14 Australian drug and device companies, which will also receive mentoring and support from partners including CSL and Roche Diagnostics.
A profile of six life-science ventures that graduated from Melbourne bioincubator Jumar's debut program, one of which, Tessara Therapeutics, won a $3 million research grant in December.
Breakthrough Victoria, the Victorian government's $2bn investment fund, appoints Rod Bristow, previously Investible's CEO, as chief executive, succeeding inaugural CEO Grant Dooley. The article also recalls Seer Medical's administration.
Breakthrough Victoria has appointed Rod Bristow, previously Investible's CEO, as its chief executive, citing a 33-company portfolio, over $300 million invested and $1.06 billion attracted from co-investors.
Breakthrough Victoria names Rod Bristow chief executive, citing his Investible and financial-services background, and outlines the fund's portfolio scale, co-investment record, and ambitions for patient capital and eventual exits.
Telix, an ASX-listed radiopharmaceutical maker headquartered in Melbourne, is preparing a dual US listing; the piece also covers revenue growth, cancer trial results and recalls its 2017 float.
Breakthrough Victoria defends its spending and investment record against critics urging its abolition, pointing to portfolio companies, university partnerships and recent backing of startups including Aravax.
Breakthrough Victoria's media release marks three years, citing more than $300 million committed across direct investments, a fund, a grant and university partnerships, and discusses its Aravax and Seer Medical investments.
Manufacturing news roundup: CSL opens a Melbourne headquarters, Hazer raises $14.7m, Iluka advances its refinery with federal loan backing, plus executive appointments at Lithium Australia, Vast Solar and CSIRO's board.
Cicada Innovations is opening a health-tech incubator at Sydney's Westmead precinct with NSW government grant backing, working with Brandon Capital and Brandon BioCatalyst to help researchers commercialise medical discoveries.
Deep tech incubator Cicada Innovations is opening a health-focused facility at Sydney's Westmead precinct with Investment NSW backing, working with Brandon Capital and Brandon BioCatalyst to help early medical startups commercialise.
Cardiac pacing company EBR Systems says its SOLVE-CRT trial hit its safety and efficacy goals early, keeping a 2024 US approval bid on course; the article also recalls its 2021 ASX listing.
Briefs roundup: Starpharma names a new CFO, Weld Australia urges trades diversity, the Economic Accelerator bill passes, H2X Global enters AWS's clean energy accelerator, and A.H. Beard partners with the Sleep Health Foundation.
Calix received a $1 million federal grant for its Bacchus Marsh biotech operations, while CSL is dedicating floors of its new Melbourne headquarters to a biotechnology incubator with university and research institute partners.
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Cut Through Venture·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·Forbes Australia·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com·Forbes Australia
Ferret research found Ena Respiratory's INNA-051 nasal spray sharply lowered coronavirus levels; the biotech has banked an $11.7 million Series A and aims to begin human trials within months.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio
A biotech spin-out from the University of Melbourne has raised a Series A to develop a gum disease vaccine, backed by a biomedical translation fund, a large biotech company and the university itself.
Also Brandon BioCatalyst portfolio·Startup Daily·denteric.com·denteric.com·@AuManufacturing·Startup Daily
Brandon Capital's blog reports a first close of $210 million toward its $250 million MRCF 5 biotech fund, with super funds and CSL backing, and recalls past portfolio sales of Spinifex and Fibrotech.
Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily